Sanara MedTech Inc. (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies for the surgical market, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net revenue increase of 5% to $27.5 million in Q4 2025, compared to $26.3 million in the same quarter of the previous year. This growth was attributed to increased sales of soft tissue repair products, particularly CellerateRX Surgical, as the company expanded its market presence and distribution network. However, the company also reported a net loss from continuing operations of $1.1 million for the quarter, a decline from a net income of $0.9 million in Q4 2024. For the full year 2025, Sanara achieved a net revenue of $103.1 million, marking a 19% increase from $86.7 million in 2024. The company reaffirmed its financial guidance for 2026, expecting net revenue growth of 13% to 17%, projecting revenues between $116 million and $121 million. The management expressed confidence in their strategic direction and operational execution, aiming for sustainable long-term growth in the surgical market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.